Paper39796644
Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.
Bruinsma RS and 9 others. Cancers (Basel), 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review. Papers, record 39796644. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796644
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20516441 | Accumulation of segmental alterations determines progression in neuroblastoma. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20516441 | PubMed |
| 2 | 26864375 | Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. | Pediatr Blood Cancer | 2016 | https://conductscience.org/library/papers/26864375 | PubMed |
| 3 | 29296183 | Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. | Oncotarget | 2017 | https://conductscience.org/library/papers/29296183 | PubMed |
| 4 | 18478485 | Risk estimation of neuroblastoma patients using molecular markers. | Klin Padiatr | 2008 | https://conductscience.org/library/papers/18478485 | PubMed |
| 5 | 15591897 | New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. | J Pediatr Hematol Oncol | 2004 | https://conductscience.org/library/papers/15591897 | PubMed |
| 6 | 25775931 | Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. | BMJ | 2015 | https://conductscience.org/library/papers/25775931 | PubMed |
| 7 | 22146831 | Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). | Br J Cancer | 2011 | https://conductscience.org/library/papers/22146831 | PubMed |
| 8 | 16306521 | Chromosome 1p and 11q deletions and outcome in neuroblastoma. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16306521 | PubMed |
| 9 | 10561284 | Molecular biology of neuroblastoma. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561284 | PubMed |
| 10 | 12764740 | FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. | Med Pediatr Oncol | 2003 | https://conductscience.org/library/papers/12764740 | PubMed |
| 11 | 34636058 | Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond. | Int J Cancer | 2022 | https://conductscience.org/library/papers/34636058 | PubMed |
| 12 | 29378002 | Neuroblastoma. | Jpn J Clin Oncol | 2018 | https://conductscience.org/library/papers/29378002 | PubMed |
| 13 | 20879880 | Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20879880 | PubMed |
| 14 | 10379019 | Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10379019 | PubMed |
| 15 | 22529259 | Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22529259 | PubMed |
| 16 | 19047291 | The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19047291 | PubMed |
| 17 | 19171713 | Overall genomic pattern is a predictor of outcome in neuroblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19171713 | PubMed |
| 18 | 22976801 | Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22976801 | PubMed |
| 19 | 16549855 | Evaluation of the quality of prognosis studies in systematic reviews. | Ann Intern Med | 2006 | https://conductscience.org/library/papers/16549855 | PubMed |
| 20 | 35100718 | Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. | JCO Precis Oncol | 2019 | https://conductscience.org/library/papers/35100718 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41733731 | Identification of potential clinical markers associated with prognosis of neuroblastoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41733731 | PubMed |
| 41595154 | Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41595154 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796644
GET https://conductscience.org/api/papers/v1/39796644/references?page=2